37 results about "Pefloxacin" patented technology

The invention discloses a preparation method of anti-fluoroquinolone rabbit monoclonal antibodies and application thereof. Six fluoroquinolone medicaments are chosen in the invention and coupled with Bovine serum albumin (BSA) to synthesize immunoantigens respectively. The above six immunoantigens are injected subcutaneously in the backs of immune rabbits after being mixed together. The anti-fluoroquinolone rabbit monoclonal antibodies are obtained by hybridoma technique. Rabbit monoclonal antibodies, which are superior to rat monoclonal antibodies, are prepared in the invention. More antigenic determinants are identified when rabbits are chosen as the experimental animal instead of rats. In addition, more integrated experiments can be carried out in rabbit spleens, since the spleens of rabbits are larger than that of rats. The invention provides the possibility of high throughput screening for fusion cells. The anti-fluoroquinolone antibodies of wide-adaptability in the invention has good detection effect on fluoroquinolones, such as enrofloxacin, ofloxacin, Difloxacin, Pefloxacin, Fleroxacin, Danofloxacin, etc., thus making it applicable to fluoroquinolone residue detection on food, forage and environmental samples.

The invention discloses a rabbit monoclonal antibody based ciprofloxacin residue analysis enzyme-linked immune adsorption kit. In the ciprofloxacin detection, the IC50 value of the kit is 1.41ng / mL, the linear fitting equation of an inhibition ratio curve is y = 0.0239x - 1.3159, the detection range is between 0.19 and 10ng / mL, and the lowest detection limit is 0.095ng / mL. The ciprofloxacin antibody in the kit has higher specificity, and has lower crossing-over rate with other quinolone micromolecules; and the cross reaction rates between the ciprofloxacin antibody and enrofloxacin, ofloxacin, norfloxacin, fleroxacin or pefloxacin are 28.8 percent, 13.1 percent, 11 percent, 22.6 percent and 20.4 percent respectively. The ciprofloxacin antibody has no cross reaction with other antibiotics and sulfanilamide medicaments. The kit is suitable for detecting ciprofloxacin residue in samples of milk, urine and the like. The kit can detect samples on a large scale at the same time, is convenient and quick, has quite important realistic significance for on-site supervision and trace analysis, meanwhile greatly reduces the detection cost, and has potential economic value.

The invention provides an aspartate quinolone antibiotics water-soluble salt and the injection formulation thereof, including sparfloxacin, gatifloxacin, rufloxacin, pefloxacin, tosufloxacin, moxifloxacin, and so on; the invention improves the water solubility of quinolone antibiotics and enhances the anti-bacterial effect of quinolone antibiotics. Compared with the oral liquid of quinolone drugs of the prior art, the invention has the advantages that: water solubility of the drug is good, as the drug enters the blood directly, the invention can not only achieve treatment function rapidly, but can also be absorbed by the human body fully, and the invention has significant effects in the two aspects of fast onset of action and low consumption. Compared with the injection of the quinolone drugs of the prior art, the invention has the advantages that: due to the existence of the L-aspartate, the antibacterial activity of quinolone drugs can be enhanced.

The invention relates to an injection for treating animal diarrhoea which is prepared from green chiretta extract, methanesulfonic acid pefloxacin, auxiliary solvent, anti-oxidant, benzyl alcohol and water for injection.

The invention discloses a method and special immune affinity adsorbent for extracting quinolone compound and / or sulfonamide compound. The immune affinity adsorbent consists of a solid-phase carrier and Norfloxacin monoclonal antibody and / or sulfamethoxazole monoclonal antibody coupled with the carrier, wherein the Norfloxacin monoclonal antibody and the sulfamethoxazole monoclonal antibody are obtained by taking Norfloxacin hapten, sulfamethoxazole hapten and carrier protein conjugate as immunogen; the quinolone compound is at least one of the following 13 types of compounds: Ciprofloxacin, Norfloxacin, Pefloxacin, Ofloxacin, Enoxacin, Marbofloxacin, Lomefloxacin, Danofloxacin, Enrofloxacin, Sarafloxacin, Difloxacin, Oxolinic acid and Flumequine; and the sulfonamide compound is at least one of the following 6 types of compounds: sulfapyridine, sulfathiazole, sulphapyridine, sulfamethizole, sulfamonomethoxine and sulfamethoxazole.

The invention discloses a method for determining 10 quinolone antibiotics in bean sprouts by an ultra-high performance liquid chromatography-tandem mass spectrometry, which is characterized by comprising the following steps of: preprocessing; preparing a standard solution; obtaining a liquid chromatography mass spectrogram and a regression equation; and analyzing and detecting samples by the ultra-high performance liquid chromatography-tandem mass spectrometry. A ultra-high performance liquid chromatography-electrospray tandem mass spectrometry is adopted in this study to carry out an analysisand determination of enrofloxacin, ciprofloxacin, norfloxacin, pefloxacin, ofloxacin, sarafloxacin, danofloxacin, sparfloxacin, fleroxacin and lomefloxacin in the bean sprouts. Sample extraction conditions, purification means, liquid chromatography-mass spectrum parameters and the like are optimized and the matrix effect of the method is evaluated. The result shows that an establishment of the method solves the problem of a simultaneous determination of various quinolone antibiotics in the bean sprouts and provides a technical reference for risk assessment and government supervision.

The invention relates to a method for preparing a gallic acid quinolone drug salt and a preparation method thereof. By adopting the method provided by the invention, a series of gallic acid quinolone drug salts are prepared, such as gallic acid norfloxacin, gallic acid ciprofloxacin, gallic acid ofloxacin, gallic acid levofloxacin, gallic acid prulifloxacin, gallic acid pefloxacin, gallic acid mosifloxacin and the like. The gallic acid quinolone drug salt prepared by the invention has pharmacological action of quinolone and also has the pharmacological action of gallic acid, two different pharmacological action mechanisms can realize synergic antibacterial action, and the gallic acid quinolone drug salt can be prepared into tablets, dispersible tablets and capsules used for oral administration and injection used for injection and also can be prepared into suppository and lotion which are used for local application (rectum application and vagina application). The quinolone drug is a broad spectrum antibiotic, and the gallic acid has antibacterial, antiviral and antitumour functions. The preparation method of the quinolone drug salt can mutually enhance antibacterial action after being applied.

The invention is characterized in that uniform formula, process and equipment are used for industrial production of pefloxacin mesilate liposome medicine composition in the forms of injection and oral preparation by using a molecular dispersion method. The invention provides the mole ratio of the components in a formula of the pefloxacin mesilate liposome medicine composition. The invention also provides steps, methods and specific embodiments for preparing the pefloxacin mesilate liposome medicine composition in the forms of lyophilized injection and oral preparation. The pefloxacin mesilate liposome medicine composition can be used for resisting bacteria.

The invention belongs to the technical field of pharmacy and discloses a method for synthesizing pefloxacin mesylate by utilizing solid formaldehyde instead of liquid formaldehyde. The method is characterized in that solid formaldehyde, methanoic acid and norfloxacin are methylated under a given temperature condition, an intermediate product is crystallized and re-crystallized in 83% ethanol solution after directly having the salt forming reaction with methanesulfonic acid without being separated to obtain the pefloxacin mesylate containing two crystal waters, and the yield can reach 93.2 percent. By adopting the solid formaldehyde, transportation and storage are simple and convenient, the consumption of the formaldehyde is reduced, and economical and environment-friendly effects are achieved; the separation process of the intermediate product is omitted, so that the loss of the intermediate product is reduced, the product yield is increased, the method is applicable to the industrial production, and the quality conforms to the pharmacopeia 2010 version.

An anti-quinolone antibiotic class specific monoclonal antibody hybridoma cell strain YH6 and an application thereof belong to the technical field of immunochemistry. The monoclonal cell strain YH6 is preserved in China General Microbiological Culture Collection Center with the preservation number of CGMCC No.12024. A monoclonal antibody secreted by the YH6 is detected by indirect competitive enzyme-linked immunosorbent assay, and has cross reaction with the following 21 pyrethroids: norfloxacin, ofloxacin, enrofloxacin, ciprofloxacin, flumequine, nafloxacin, enoxacin, lomefloxacin, levofloxacin, pefloxacin, nalidixic acid, danofloxacin, pyridine acid, cinoxacin, oxolinic acid, marbofloxacin, pazufloxacin, sparfloxacin, gatifloxacin, orbifloxacin and fleroxacin, and the IC50 value of the monoclonal antibody is 0.1-50 ng / mL. The class specific monoclonal antibody can be used for developing colloidal gold immunochromatographic test strips and immunosensors, provides a raw material for the immunodetection of quinolone antibiotic residues in foods, and has practical application values.

The invention discloses a pefloxacin coupling compound with general formula (I), which comprises coupling compounds of pefloxacin hapten and bovine serum albumin of carrier substance which can produce immunogen or egg albumin. Thereinto, n stands for molecular number of pefloxacin combined with a bovine serum albumin molecule, the said n is an integer between one and twenty, and BSA stands for bovine serum albumin with 6.6KDa-6.9KDa of molecular weight. The invention also discloses a process for preparing the said coupling compound, which consists of joining pefloxacin and carrier substance which can produce immunogen to obtain the said coupling compound which induces immune system of animals to produce antibody. By immuning white rabbits from New Zealand, the pefloxacin coupling compound of this invention has prepared antiserum with 1:512,000 of potency, of which the lowest check limit is 0.01ppb. The invention is characterized in that it is simple, rapid, specific, exact and so on, which provides a foundation for preparing enzyme immunoassay agent box of pefloxacin.

The invention provides a pefloxacin mesylate injection, which comprises the following components in percent by weight: 8-10 percent of pefloxacin, 0.05-0.5 percent of antioxidant, 0.02-0.1 percent of complexing agent and the balance of other pharmaceutic adjuvants. The invention also provides a method for preparing the pefloxacin mesylate injection, which comprises the following steps of: (1) taking the 8-10 percent of pefloxacin, the 0.05-0.5 percent of antioxidant, the 0.02-0.1 percent of complexing agent and the balance of other pharmaceutic adjuvants for mixing, and dissolving; (2) adjusting the pH value of the solution obtained in the step 1; and (3) filtering the solution obtained in the step 2 by adopting a filtration membrane. The pefloxacin mesylate injection prepared by the method has the advantages of high stability and small vascular stimulation.

The invention discloses a new application of quinolone compounds as bactericides in prevention and treatment of bacterial diseases and citrus canker of crops. The quinolone compounds comprise floroxacin, enofloxacin, gatifloxacin, moxifloxacin hydrochloride, enrofloxacin, marbofloxacin, floxacin, mononorfloxacin mesylate, prulifloxacin, Balofloxacin, pazufloxacin mesylate, pipemidic acid, sparfloxacin, difloxacin hydrochloride, lomefloxacin hydrochloride, pefloxacin, tosufloxacin mesylate, Cinoxacin, galafloxacin, besifloxacin hydrochloride, ofloxacin, nalidixic acid, Clinafloxacin and Sitafloxacin. The quinolone compounds can be used for preventing and treating bacterial diseases caused by citrus canker pathogens, especially gatifloxacin, moxifloxacin hydrochloride, mononorfloxacin mesylate, sparfloxacin, tosufloxacin mesylate, clinafloxacin and sitafloxacin, has excellent bacteriostatic activity on citrus canker pathogens, and can be used for preventing and treating bacterial diseases of crops.

The invention discloses an immuno-gold labeling card for the general detection of fluoroquinolones and a preparation method thereof. The immuno-gold labeling card comprises a colloidal gold pad and a chromatography membrane. The colloidal gold pad is sprayed with a monoclonal antibody protein generated by a hybridoma cell strain, wherein the hybridoma cell strain is labeled by colloidal gold and the preservation number of the hybridoma cell strain is CCTCC NO.C2015221. A detection line on the chromatography membrane is sprayed with a conjugate of enrofloxacin and cationized bovine serum albumin. A control line on the chromatography membrane is sprayed with a Goat Anti-Mouse secondary antibody IgG(H+L). According to the invention, a monoclonal antibody, which is high in sensitivity and strong in universality for ciprofloxacin, enrofloxacin, norfloxacin, pefloxacin, enoxacin and the like when measured through the indirect competition ELISA assay, is adopted. After that, the monoclonal antibody is applied to the immuno-gold labeling card for the detection of fluoroquinolones. Therefore, the prepared immuno-gold labeling card is still high in sensitivity and strong in universality for target drugs. In this way, the immuno-gold labeling card can be used for the rapid and qualitative screening of mainly fluoroquinolones in various fields.

The invention discloses novel application of a fluoroquinolone medicine and application of the fluoroquinolone medicine in preparation of a sensitizer of a pseudomonas aeruginosa (P.aeruginosa) inhibitor. The fluoroquinolone medicine is prepared from gemifloxacin, sparfloxacin, enrofloxacin, ciprofloxacin, sarafloxacin, moxifloxacin, pefloxacin, tosufloxacin, orbifloxacin, prulifloxacin, marbofloxacin, levofloxacin, flumequine or / and pazufloxacin; the pseudomonas aeruginosa is pseudomonas aeruginosa DK2 or PAO1; the pseudomonas aeruginosa inhibitor is polymyxin B or colistin.

The invention relates to a small-volume pefloxacin mesylate freeze-dried powder injection, a preparation method and a producing device thereof. An anti-oxidant is added to raw materials and then a 7ml tube-made penicillin bottle is filled with the raw materials to obtain the freeze-dried powder injection. The preparation method includes following steps: (1) mixing, stirring and dissolving water for injection, pefloxacin mesylate, mannitol and the anti-oxidant; (2) adding activated charcoal, performing filtration and precision filtration to obtain a solution; and (3) adding the water for injection to prepare a diluted solution, maintaining the temperature, filling the 7ml tube-made penicillin bottle with the diluted solution, freeze-drying the diluted solution, pressing a plug on the bottle and capping the bottle to obtain the freeze-dried powder injection. The producing device includes a thermal-insulating drug-blending pot, a second Grundfos pump, a pump stick filter, a second sterilization filter core, a sterilized thermal-insulating liquid storage tank, a first Grundfos pump, a first sterilization filter core, a filling machine and a freeze-drying machine, wherein the units are connected through thermal-insulating pipelines successively. The preparation method and the producing device improve quality of the freeze-dried powder injection, effectively increase yield and reduce energy consumption, reduce package size, reduce costs during packaging and transportation, reduce a filling amount, greatly reduce energy consumption during a freeze-drying step and further reduce the cost.

The invention discloses a pefloxacin aldolase 4-aryl thiosemicarbazides derivative. The structural formula is shown in formula I in the specification, wherein the substituent group Ar is a benzene ring, a substituted benzene ring, a pyridine ring, a furan ring or a thiofuran ring. The invention also discloses a preparation method and an application of the pefloxacin aldolase 4-aryl thiosemicarbazides derivative. The pefloxacin aldolase 4-aryl thiosemicarbazides derivative has the advantages that the three types of superior pharmacophores of tricyclic fluoroquinolone keel, imine Schiff base and thiourea are compounded, so that the anti-tumor activity of a new compound is improved, and the toxic or side effect to normal cells is decreased; the derivative can be used as an anti-tumor active substance to develop an anti-tumor drug with a new structure.

The invention relates to fructose injection of an antibiotic medicine. The fructose injection of the antibiotic medicine consists of antibiotics, fructose and water and also comprises proper additives, wherein the antibiotics comprise gatifloxacin, levofloxacin, ciprofloxacin, pazufloxacin, fleroxacin, sparfloxacin, moxifloxacin, pefloxacin, rufloxacin, lomefloxacin, norfloxacin, caderofloxacin, azithromycin, telithromycin, ornidazole, secnidazole, tinidazole, metronidazole, clindamycin, lincomycin, fluconazole, etimicin, netilmicin, amikacin as well as medicinal acid addition salt, esterification compounds, derivatives and the like; the fructose injection is prepared from the antibiotics; the advantages that the injection is convenient to use and takes effect rapidly are achieved; and compared with the glucose injection, the fructose injection is easier to absorb and utilize, more suitable for antisepsis and anti-inflammation, energy supply and body liquid supplementation of patientssuffering from diabetes, heart diseases and liver diseases, and enlarges the use range.

The invention relates to the technical field of biologics, and discloses fluoroquinolone medicine cluster specific immunoaffinity chromatography glue which is prepared by purifying monoclonal antibody protein secreted from a hybridoma cell strain of which the preservation serial number is CCTCC NO.C2015221 and implementing chemical crosslinking with CNBr-activated Sepharose-4B glue so as to obtain a solid phase antibody. Monoclonal antibodies such as enrofloxacin, ciprofloxacin, norfloxacin, pefloxacin and enoxacin with high sensitivity and high universality recognition and combination are applied to study and development of immunoaffinity chromatography glue, the product is high in selectivity, good in enrichment and good universality for target articles, namely medium interference of a sample to be tested can be effectively removed, high-purity target article can be also obtained for machine tests, and furthermore the target article can be enriched, so that the application field of HPLC-FLD / LC-MS-MS detection can be greatly widened.

The invention belongs to the field of biomedicine, and discloses a use of pefloxacin in the preparation of drugs for treatment and prevention of hyperlipemia or atherosclerosis. The pefloxacin can beprepared into any pharmaceutically acceptable preparation, and a new medical use of pefloxacin compounds is opened up, the current deficiencies in the drugs for the treatment and prevention of the hyperlipemia or the atherosclerosis are overcome, and a therapeutic role is achieved from anti-inflammatory and lipid-lowering ways; and meanwhile, the pefloxacin is a clinically verified broad-spectrumantibacterial drug, wide in source, low in price, high in pharmacological effect and high in safety, and belongs to the new use of old drugs, and an economical and safe drug choice is provided for themajority of patients with cardiovascular disease.

The invention provides a fructose injection of an antibiotic drug. The injection is composed of antibiotics, fructose and water. The injection also can contain proper additives. The antibiotic comprise gatifloxacin, levofloxacin, ofloxacin, ciprofloxacin, pazufloxacin, fleroxacin, sparfloxacin, moxifloxacin, pefloxacin, rufloxacin, lomefloxacin, norfloxacin, caderofloxacin, azithromycin, telithromycin, ornidazole, secnidazole, tinidazole, metronidazole, clindamycin, lincomycin, fluconazole, etimicin, netilmicin, amikacin and medicinal acid additive salts, esterified compounds, derivatives and the like. The antibiotics are prepared into the fructose injection. Besides the advantages of convenience in use and quickness to take effect of the injection, compared with a gluconic infection, the injection provided by the invention is more easily absorbed and utilized, is more suitable for preventing bacteria and diminishing inflammation, supplying energy and supplementing body fluids for patients with diabetes, heart disease and liver disease, so that the application range of the injection is expanded.

The invention belongs to the technical field of preparation of veterinary drugs and in particular relates to a veterinary pefloxacin mesylate injection and a preparation method thereof. The veterinary pefloxacin mesylate injection comprises the following components of 1-10 percent (w / v) of pefloxacin mesylate, 0.05-1 percent (w / v) of complexing agent, 0.05-1 percent (w / v) of antioxidant, 1-50 percent (w / v) of pH buffer agent and the balance of thinning agent in the total 100 percent (w / v). Compared with the prepared injection in the prior art, the provided veterinary pefloxacin mesylate injection has the advantage that the drug quality is stable. Through long-term reserved sample observation and result comparison, the provided veterinary pefloxacin mesylate injection is stable in pH value and pharmaceutical effect, and the preparation method is feasible; therefore, the aim of the invention is well fulfilled.

The invention provides a pefloxacin mesylate injection, which is characterized in that the weight percentage of the injection prescription is: pefloxacin mesylate 90%-98%, sodium thiosulfate 1%-3%, Activated carbon 1% to 3%, water for injection is added to 5000ml. The prescription of the injection is scientific and reasonable, the preparation process is simple, and the finished product has good stability.

The invention provides a detection method of four forbidden fluoroquinolone drug residues in aquaculture water, and belongs to the technical field of environment quality security detection. The methodcomprises the following steps: taking 50mL of a water sample, adding an acetic acid-acetonitrile solution with the same volume to extract, and shaking out for 30min; adding an appropriate amount of sodium chloride, mixing for 1min, and standing for layering; taking 25mL of supernate, and concentrating, namely blowing the supernate with nitrogen at 40 DEG C till to nearly dry; adding 1mL of 0.1% formic acid-water-methanol (90+10) to re-dissolve, filtering through a filter membrane of 0.22 micron for future detection. The detection method disclosed by the invention has the advantages that the pretreatment for detecting the residues of ofloxacin, pefloxacin, lomefloxacin and norfloxacin in the aquaculture water is simple and convenient, the liquid chromatogram-tandem mass spectrometry and multiple reaction monitoring modes are adopted, the determination on the nature and the quantitation is accurate, the sensitivity is high, the reproducibility is good. Theoretical support of the detection method is provided for formulating related industry standard by the nation.

The invention discloses a method for detecting veterinary drugs in water based on cadmium telluride quantum dots. The method comprises the following steps: preparing water-soluble N-acetylcysteine (NAC) modified CdTe quantum dot powder with different wavelengths; preparing an NAC-CdTe quantum dot solution; adding a series of veterinary drug solutions with known concentrations into the prepared NAC-CdTe quantum dot solution, and establishing a relationship between the fluorescence intensity and the concentrations of the veterinary drug solutions according to the detected fluorescence intensity of the solutions; and adding a solution to be detected into the prepared NAC-CdTe quantum dot solution, detecting the fluorescence intensity of the solution to be detected, and determining the concentration of the veterinary drug solution in the solution to be detected based on the relationship between the fluorescence intensity and the concentration of the veterinary drug solution. According to the present invention, the veterinary drugs such as malachite green, pefloxacin, chloramphenicol and the like in water are detected based on the NAC-CdTe quantum dots, such that advantages of simpleness, rapidness, high sensitivity and the like are provided, and the important significance is provided for the detection of the veterinary drug residues in aquatic products and environments.

The invention provides a pefloxacin mesylate injection, which comprises the following components in percent by weight: 8-10 percent of pefloxacin, 0.05-0.5 percent of antioxidant, 0.02-0.1 percent of complexing agent and the balance of other pharmaceutic adjuvants. The invention also provides a method for preparing the pefloxacin mesylate injection, which comprises the following steps of: (1) taking the 8-10 percent of pefloxacin, the 0.05-0.5 percent of antioxidant, the 0.02-0.1 percent of complexing agent and the balance of other pharmaceutic adjuvants for mixing, and dissolving; (2) adjusting the pH value of the solution obtained in the step 1; and (3) filtering the solution obtained in the step 2 by adopting a filtration membrane. The pefloxacin mesylate injection prepared by the method has the advantages of high stability and small vascular stimulation.

The invention discloses an analogue from pefloxacin to isocryptolepine as well as a preparation method and application thereof. The analogue is characterized in that a chemical structure is shown as a formula I, wherein a substituent group R in the formula I can be independently -H, -OCH3, -F, -Cl or -SO2NH2. According to the isocryptolepine analogue disclosed by the invention, pefloxacin is taken as a raw material, so that effective chemical construction from a fluoroquinolone structure to an indoloquinoline skeleton is realized, a new way for structural modification of isocryptolepine is expanded, complementary advantage structures of fluoroquinolone medicines and natural indoloquinoline alkaloids are achieved, further, the anti-tubercle bacillus activity and the anti-drug resistance of the compound are improved, the toxicity to normal cells is reduced, and the compound can be further developed as an anti-tubercle medicine with a brand new structure.